SNDA submitted to FDA for venetoclax, acalabrutinib combo in CLL
The US Food and Drug Administration (FDA) received the supplemental New Drug Application for venetoclax (VENCLEXTA) and acalabrutinib (Calquence), an.
The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
The US Food and Drug Administration (FDA) received the supplemental New Drug Application for venetoclax (VENCLEXTA) and acalabrutinib (Calquence), an.

EAGLE, which stands for Exchange for Advanced Global Learning and Education, fulfills SOHO’s longstanding mission to educate and to expand global access to world-class clinical training.

Lawrence N. Shulman, MD, a medical oncologist at the University of Pennsylvania’s Abramson Cancer Center, discussed US cancer surveillance challenges in a recent interview with SOHO Insider.

A next-generation blood test is able to diagnosis and monitor multiple myeloma (MM) and its precursor conditions by utilizing single-cell sequencing to profile circulating tumor cells (CTCs) in the blood.
Benefits of membership include:
The Career Center provides SOHO members with the ability to find jobs in the field of Hematologic Oncology along with a variety of career advice. Select the 'Career Center' button to explore new job opportunities and career information.
The Career Center Allows SOHO Members to:
To access the SOHO Career Center click the following link.